FOXA1, GATA3 and PPARIγ Cooperate to drive luminal subtype in bladder cancer: A molecular analysis of established human cell lines

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Warrick, Joshua I ^a,b   Walter, Vonn ^b   Yamashita, Hironobu ^a   Chung, Eunah ^c   Shuman, Lauren ^a,b   Amponsa, Vasty Osei ^a   Zheng, Zongyu ^a   Chan, Wilson ^a,b   Whitcomb, Tiffany L ^b   Yue, Feng ^b   Iyyanki, Tejaswi ^b   Kawasawa, Yuka I ^b   Kaag, Matthew ^b   Guo, Wansong ^b   Raman, Jay D ^b   Park, Joo Seop ^c   Degraff, David J ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOXA1 PROTEIN, HUMAN; GATA3 PROTEIN, HUMAN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER;

ANIMAL; BLADDER TUMOR; CLASSIFICATION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION STUDY; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; RAT; REGULATORY SEQUENCE; SEQUENCE ANALYSIS; TUMOR CELL LINE; UROTHELIUM;

ANIMALS; BASE SEQUENCE; BIOMARKERS, TUMOR; CELL LINE, TUMOR; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC ASSOCIATION STUDIES; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; PPAR GAMMA; RATS; REGULATORY SEQUENCES, NUCLEIC ACID; SEQUENCE ANALYSIS, RNA; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 85002807915     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38531     Document Type: Article

References (55)

1. Siegel, R. L., Miller, K. D. and Jemal, A. Cancer statistics, 2015. CA: a cancer journal for clinicians 65, 5-29, doi: 10.3322/caac.21254 (2015).
2. Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer cell 25, 152-165, doi: 10.1016/j.ccr.2014.01.009 (2014).
3. Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 18, 3377-3386, doi: 10.1158/1078-0432.CCR-12-0077-T (2012).
4. Cancer Genome Atlas Research, N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322, doi: 10.1038/nature12965 (2014).
5. Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America 111, 3110-3115, doi: 10.1073/pnas.1318376111 (2014).
6. Lerner, S. P. et al. Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. Bladder Cancer 2, 37-47, doi: 10.3233/BLC-150037 (2016).
7. Hedegaard, J. et al. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer cell 30, 27-42, doi: 10.1016/j.ccell.2016.05.004 (2016).
8. McConkey, D. J. et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. European urology, doi: 10.1016/j. eururo.2015.08.034 (2015).
9. Reddy, O. L. et al. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. The American journal of pathology 185, 1385-1395, doi: 10.1016/j.ajpath.2015.01.014 (2015).
10. Strand, D. W. et al. Deficiency in metabolic regulators PPARgamma and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. The American journal of pathology 182, 449-459, doi: 10.1016/j. ajpath.2012.10.007 (2013).
11. Varley, C. L., Stahlschmidt, J., Smith, B., Stower, M. and Southgate, J. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. The American journal of pathology 164, 1789-1798 (2004).
12. Eriksson, P. et al. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC medical genomics 8, 25, doi: 10.1186/s12920-015-0101-5 (2015).
13. Bell, S. M. et al. Kruppel-like factor 5 is required for formation and differentiation of the bladder urothelium. Developmental biology 358, 79-90, doi: 10.1016/j.ydbio.2011.07.020 (2011).
14. Bock, M. et al. Identification of ELF3 as an early transcriptional regulator of human urothelium. Developmental biology 386, 321-330, doi: 10.1016/j.ydbio.2013.12.028 (2014).
15. Yu, Z., Mannik, J., Soto, A., Lin, K. K. and Andersen, B. The epidermal differentiation-associated Grainyhead gene Get1/Grhl3 also regulates urothelial differentiation. The EMBO journal 28, 1890-1903, doi: 10.1038/emboj.2009.142 (2009).
16. Varley, C. L. and Southgate, J. Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol 60, 435-441, doi: 10.1016/j.etp.2008.04.009 (2008).
17. Choi, W. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature reviews. Urology 11, 400-410, doi: 10.1038/nrurol.2014.129 (2014).
18. DeGraff, D. J. et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PloS one 7, e36669, doi: 10.1371/journal.pone.0036669 (2012).
19. Karni-Schmidt, O. et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. The American journal of pathology 178, 1350-1360, doi: 10.1016/j.ajpath.2010.11.061 (2011).
20. Mysorekar, I. U., Mulvey, M. A., Hultgren, S. J. and Gordon, J. I. Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. The Journal of biological chemistry 277, 7412-7419, doi: 10.1074/jbc.M110560200 (2002).
21. Biton, A. et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep 9, 1235-1245, doi: 10.1016/j.celrep.2014.10.035 (2014).
22. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607, doi: 10.1038/nature11003 (2012).
23. Earl, J. et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC genomics 16, 403, doi: 10.1186/s12864-015-1450-3 (2015).
24. Cunha, G. R. and Donjacour, A. Mesenchymal-epithelial interactions: technical considerations. Prog Clin Biol Res 239, 273-282 (1987).
25. Rigby, C. C. and Franks, L. M. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. British journal of cancer 24, 746-754 (1970).
26. Bubenik, J. et al. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. International journal of cancer. Journal international du cancer 11, 765-773 (1973).
27. Grossman, H. B., Wedemeyer, G. and Ren, L. UM-UC-1 and UM-UC-2: characterization of two new human transitional cell carcinoma lines. The Journal of urology 132, 834-837 (1984).
28. Grossman, H. B., Wedemeyer, G., Ren, L., Wilson, G. N. and Cox, B. Improved growth of human urothelial carcinoma cell cultures. The Journal of urology 136, 953-959 (1986).
29. OToole, C., Nayak, S., Price, Z., Gilbert, W. H. and Waisman, J. A cell line (SCABER) derived from squamous cell carcinoma of the human urinary bladder. International journal of cancer. Journal international du cancer 17, 707-714 (1976).
30. Rasheed, S., Gardner, M. B., Rongey, R. W., Nelson-Rees, W. A. and Arnstein, P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. Journal of the National Cancer Institute 58, 881-890 (1977).
31. Nayak, S. K., OToole, C. and Price, Z. H. A cell line from an anaplastic transitional cell carcinoma of human urinary bladder. British journal of cancer 35, 142-151 (1977).
32. Fogh, J., Fogh, J. M. and Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59, 221-226 (1977).
33. Fogh, J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. National Cancer Institute monograph, 5-9 (1978).
34. Trapnell, C., Pachter, L. and Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111, doi: 10.1093/bioinformatics/btp120 (2009).
35. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7, 562-578, doi: 10.1038/nprot.2012.016 (2012).
36. Anders, S. and Huber, W. Differential expression analysis for sequence count data. Genome biology 11, R106, doi: 10.1186/gb-2010-11- 10-r106 (2010).
37. Tusher, V. G., Tibshirani, R. and Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 98, 5116-5121, doi: 10.1073/pnas.091062498 (2001).
38. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research 43, e47, doi: 10.1093/nar/gkv007 (2015).
39. Langmead, B. and Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357-359, doi: 10.1038/nmeth.1923 (2012).
40. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079, doi: 10.1093/bioinformatics/btp352 (2009).
41. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Molecular cell 38, 576-589, doi: 10.1016/j.molcel.2010.05.004 (2010).
42. Stark, R. and Brown, G. DiffBind: Differential Bindign Analysis of ChIP-Seq Peak (2011).
43. Rebouissou, S. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science translational medicine 6, 244-291, doi: 10.1126/scitranslmed.3008970 (2014).
44. Dabney, A. R. Classification of microarrays to nearest centroids. Bioinformatics 21, 4148-4154, doi: 10.1093/bioinformatics/bti681 (2005).
45. Clark, P. E. Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation. Urologic oncology 33, 434-436, doi: 10.1016/j.urolonc.2015.06.019 (2015).
46. Raman, J. D. and Jafri, S. M. Surgical management of bladder urothelial carcinoma with squamous differentiation. Urologic oncology 33, 429-433, doi: 10.1016/j.urolonc.2015.06.010 (2015).
47. Zhang, H. M. et al. AnimalTFDB: a comprehensive animal transcription factor database. Nucleic acids research 40, D144-149, doi: 10.1093/nar/gkr965 (2012).
48. Varley, C. L., Bacon, E. J., Holder, J. C. and Southgate, J. FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgammainduced urothelial cytodifferentiation. Cell Death Differ 16, 103-114, doi: 10.1038/cdd.2008.116 (2009).
49. Liang, Y. et al. Differential expression of GATA-3 in urothelial carcinoma variants. Human pathology 45, 1466-1472, doi: 10.1016/j. humpath.2014.02.023 (2014).
50. Martinelli, P. et al. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice. Gut 65, 476-486, doi: 10.1136/gutjnl-2014-308042 (2016).
51. He, F., Melamed, J., Tang, M. S., Huang, C. and Wu, X. R. Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas. Cancer research 75, 2017-2028, doi: 10.1158/0008-5472.CAN-14-3067 (2015).
52. Nordentoft, I. et al. Increased expression of transcription factor TFAP2alpha correlates with chemosensitivity in advanced bladder cancer. BMC cancer 11, 135, doi: 10.1186/1471-2407-11-135 (2011).
53. Clark, P. E. et al. Bladder cancer. Journal of the National Comprehensive Cancer Network : JNCCN 11, 446-475 (2013).
54. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562, doi: 10.1038/nature13904 (2014).
55. Drayton, R. M. et al. MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. Oncotarget 5, 6375-6386, doi: 10.18632/oncotarget.2221 (2014).